| All Versions |
| Contents | Index | Standard |
HL7 - Version 2.3.1
| 2.1 | 2.2 | 2.3 | 2.3.1 | 2.4 | 2.5 | 2.6 | 2.7 | 2.8 | 2.9 | 2.9.1 |
| 2.3.1 | 2.3.1 DE |
| Events | Segments | Msg. Types | Msg. Structs | Data Elements | Tables | Data Structs |
|
|
|
HL7 - Version 2.3.1 |
|
|
| Seq | Description | German Interpretation | Length | C.LEN | Table | r/o/c | Rep# | Item | Data Structure | Section |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Give Sub-ID Counter | Art der Substitution | ..4 | R | 00342 | NM | 4.8.14.1 | |||
| 2 | Administration Sub-ID Counter | Laufende Nummer der Verabreichung pro Verordnung (Station) | ..4 | R | 00344 | NM | 4.8.14.2 | |||
| 3 | Date/Time Start of Administration | Verabreichungsbeginn | ..26 | R | 00345 | TS | 4.8.14.3 | |||
| 4 | Date/Time End of Administration | Verabreichungsende | ..26 | R | 00346 | TS | 4.8.14.4 | |||
| 5 | Administered Code | Verabreichtes Medikament / Wirkstoff | ..100 | 0292 | R | 00347 | CE_0292 | 4.8.14.5 | ||
| 6 | Administered Amount | Verabreichte Menge | ..20 | R | 00348 | NM | 4.8.14.6 | |||
| 7 | Administered Units | Maßeinheit | ..60 | C | 00349 | CE | 4.8.14.7 | |||
| 8 | Administered Dosage Form | Tatsächliche Verabreichungsform | ..60 | O | 00350 | CE | 4.8.14.8 | |||
| 9 | Administration Notes | Verabreichungshinweise | ..200 | O | Y | 00351 | CE | 4.8.14.9 | ||
| 10 | Administering Provider | Verabreichende Person / Mitarbeiter | ..200 | O | Y | 00352 | XCN | 4.8.14.10 | ||
| 11 | Administered-at Location | Verabreichungsort (Adresse) | ..200 | C | 00353 | LA2 | 4.8.14.11 | |||
| 12 | Administered Per (Time Unit) | Zeiteinheit für Verabreichung | ..20 | C | 00354 | ST | 4.8.14.12 | |||
| 13 | Administered Strength | Verabreichte Wirkstoffmenge | ..20 | O | 01134 | NM | 4.8.14.13 | |||
| 14 | Administered Strength Units | Einheit zu Feld 13 | ..60 | O | 01135 | CE | 4.8.14.14 | |||
| 15 | Substance Lot Number | Chargennummer der Substanz | ..20 | O | Y | 01129 | ST | 4.8.14.15 | ||
| 16 | Substance Expiration Date | Verfalldatum der Substanz | ..26 | O | Y | 01130 | TS | 4.8.14.16 | ||
| 17 | Substance Manufacturer Name | Hersteller der Substanz | ..60 | 0227 | O | Y | 01131 | CE_0227 | 4.8.14.17 | |
| 18 | Substance Refusal Reason | Grund für Ablehnung der Medikation | ..200 | O | Y | 01136 | CE | 4.8.14.18 | ||
| 19 | Indication | Indikation | ..200 | O | Y | 01123 | CE | 4.8.14.19 | ||
| 20 | Completion Status | Status der Medikation | ..2 | 0322 | O | 01223 | ID | 4.8.14.20 | ||
| 21 | Action Code-RXA | Aktionscode RXA | ..2 | 0323 | O | 01224 | ID | 4.8.14.21 | ||
| 22 | System Entry Date/Time | Erfassungszeitpunkt | ..26 | O | 01225 | TS | 4.8.14.22 |
| Links to Other/Further HL7 Information | generated: Aug 07, 2023 (FO) | |||
| Health Level Seven, Int. (HQ) |
HL7 Germany HL7 Europe |
Frank Oemig's HL7 Site (Infos about the database) |
HL7-Experts Network | |